The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).[6]Injection site reactions were also common, reported in 3% of subjects.[8]
Bimekizumab was approved for medical use in the European Union in August 2021,[6][9][10] and in the United States in October 2023.[11][12]
In the EU, bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, non-radiographic axial spondyloarthritis, and active ankylosing spondylitis.[6]
^ abcdef"Bimzelx EPAR". European Medicines Agency (EMA). 23 June 2021. Archived from the original on 25 August 2021. Retrieved 24 August 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information. 28 (3). hdl:10665/331112.
^Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, et al. (February 2021). "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial". Lancet. 397 (10273): 487–498. doi:10.1016/S0140-6736(21)00125-2. PMID33549193. S2CID231809826.
Reis J, Vender R, Torres T (August 2019). "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis". BioDrugs. 33 (4): 391–399. doi:10.1007/s40259-019-00361-6. PMID31172372. S2CID174812750.